<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05053139</url>
  </required_header>
  <id_info>
    <org_study_id>NN7769-4514</org_study_id>
    <secondary_id>U1111-1249-4378</secondary_id>
    <secondary_id>2020-001048-24</secondary_id>
    <nct_id>NCT05053139</nct_id>
  </id_info>
  <brief_title>A Research Study Investigating Mim8 in Adults and Adolescents With Haemophilia A With or Without Inhibitors</brief_title>
  <official_title>A Multinational, Open-label, Randomised, Controlled Study to Investigate Efficacy and Safety of NNC0365-3769 (Mim8) in Adults and Adolescents With Haemophilia A With or Without Inhibitors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is investigating how Mim8 works compared to other medicines in people with&#xD;
      haemophilia A, who either have inhibitors or do not have inhibitors. Mim8 is a new medicine&#xD;
      that will be used for prevention of bleeding episodes. Mim8 works by replacing the function&#xD;
      of the missing clotting factor VIII (FVIII).&#xD;
&#xD;
      When and how often participants will receive Mim8 is dependent on their previous treatment -&#xD;
      but is otherwise decided by chance. The study will last for 72-124 weeks (17-29 months)&#xD;
      depending on how long participants will be followed before it is decided when they start&#xD;
      receiving Mim8 - the period before this is decided is called the 'run-in'. Participants will&#xD;
      have 13-17 clinic visits. Mim8 will be injected into a skinfold on the stomach with a thin&#xD;
      needle either once a week or once a month.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2, 2021</start_date>
  <completion_date type="Anticipated">March 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">September 4, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of treated bleeds</measure>
    <time_frame>No prophylaxis treatment (Arms 1 and 2): From randomisation (week 0) to end of main (Week 26)</time_frame>
    <description>Count</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of treated bleeds</measure>
    <time_frame>Prophylaxis treatment (Arms 3 and 4): From initiation of run-in (26-52 weeks prior to week 0) to week 0 and from randomisation (week 0) to end of main (Week 26)</time_frame>
    <description>Count</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of injection site reactions</measure>
    <time_frame>All subjects receiving Mim8 (Arms 2, 3 and 4): From randomisation (week 0) to end of main (week 26)</time_frame>
    <description>Count</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of anti-Mim8 antibodies</measure>
    <time_frame>All subjects receiving Mim8 (Arms 2, 3 and 4): From randomisation (week 0) to end of extension (week 52)</time_frame>
    <description>Count</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of treated spontaneous bleeds</measure>
    <time_frame>No prophylaxis treatment (Arms 1 and 2): From randomisation (week 0) to end of main (Week 26) Prophylaxis treatment (Arms 3 and 4): From initiation of run-in (26-52 weeks prior to week 0) to week 0 and from randomisation (week 0) to end of main (Week 26)</time_frame>
    <description>Count</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of treated joint bleeds</measure>
    <time_frame>No prophylaxis treatment (Arms 1 and 2): From randomisation (week 0) to end of main (Week 26) Prophylaxis treatment (Arms 3 and 4): From initiation of run-in (26-52 weeks prior to week 0) to week 0 and from randomisation (week 0) to end of main (Week 26)</time_frame>
    <description>Count</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of treated traumatic bleeds</measure>
    <time_frame>No prophylaxis treatment (Arms 1 and 2): From randomisation (week 0) to end of main (Week 26) Prophylaxis treatment (Arms 3 and 4): From initiation of run-in (26-52 weeks prior to week 0) to week 0 and from randomisation (week 0) to end of main (Week 26)</time_frame>
    <description>Count</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of target joint bleeds</measure>
    <time_frame>No prophylaxis treatment (Arms 1 and 2): From randomisation (week 0) to end of main (Week 26) Prophylaxis treatment (Arms 3 and 4): From initiation of run-in (26-52 weeks prior to week 0) to week 0 and from randomisation (week 0) to end of main (Week 26)</time_frame>
    <description>Count</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Consumption of factor product per bleed treatment (number of injections)</measure>
    <time_frame>No prophylaxis treatment (Arms 1 and 2): From randomisation (week 0) to end of main (Week 26) Prophylaxis treatment (Arms 3 and 4): From initiation of run-in (26-52 weeks prior to week 0) to week 0 and from randomisation (week 0) to end of main (Week 26)</time_frame>
    <description>Count</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in physical function domain of PEDS-QL (pediatric quality of life inventory)</measure>
    <time_frame>All subjects (Arms 1, 2, 3 and 4): From randomisation (week 0) to the end of the main part (week 26)</time_frame>
    <description>Score points Minimum score per question (best) = 0 Maximum score per question (worst) = 4 Total score for 13 questions: 0 (best) to 92 (worst)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in patient's treatment burden using the Hemo-TEM (haemophilia treatment experience measure)</measure>
    <time_frame>All subjects (Arms 1, 2, 3 and 4): From randomisation (week 0) to the end of the main part (week 26)</time_frame>
    <description>Score points&#xD;
Ranges from 0 (best) - 4 (worst) representing answers ranging:&#xD;
'Not at all difficult' - 'Extremely difficult' 'Never' - 'always' 'Not at all bothered' - 'Extremely bothered' 'Not at all interfering' - 'Extremely interfering' 'Not at all burdened' - 'Extremely burdened'</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in patient's joint pain score using Joint Pain Rating Scale</measure>
    <time_frame>All subjects (Arms 1, 2, 3 and 4): From randomisation (week 0) to the end of the main part (week 26)</time_frame>
    <description>Score points ranges from 0 = 'not at all' (best) to 4 = 'extremely' (worst)</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">230</enrollment>
  <condition>Haemophilia A</condition>
  <condition>Haemophilia A With Inhibitors</condition>
  <arm_group>
    <arm_group_label>no PPX- no PPX - Mim8 PPXQW</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants not receiving prophylaxis will not enter the run-in period. In arm 1, participants will be randomised to continue no prophylaxis (on-demand treatment with their Standard of Care FVIII concentrates) in the main part of the study (26 weeks). After the main part, participants will continue in the extension part of the study (26 weeks) on once-weekly Mim8 prophylaxis regimen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>no PPX - Mim8 PPXQW - Mim8 PPXQW</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants not receiving prophylaxis will not enter the run-in period. In arm 2, participants will be randomised to Mim8 once-weekly prophylaxis in the main part of the study (26 weeks). After the main part, participants will continue in the extension part of the study (26 weeks) on once-weekly Mim8 prophylaxis regimen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PPX - Mim8 PPXQW</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients on coagulation factor prophylaxis prior to enrolment will preferably continue the same product type and dosing frequency in the run-in period for at least 26 weeks before they can be randomised into the main part of the study. These participants will only be allowed to receive coagulation factor prophylaxis. In arm 3, participants will be randomised to once-weekly Mim8 prophylaxis regimen in the main part of the study (26 weeks). After the main part, participants will continue in the extension part of the study (26 weeks) on once-weekly Mim8 prophylaxis regimen.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PPX- Mim8 PPXQM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients on coagulation factor prophylaxis prior to enrolment will preferably continue the same product type and dosing frequency in the run-in period for at least 26 weeks before they can be randomised into the main part of the study. These participants will only be allowed to receive coagulation factor prophylaxis. In arm 4, participants will be randomised to once-monthly Mim8 prophylaxis regimen in the main part of the study (26 weeks). After the main part, participants will continue in the extension part of the study (26 weeks) on once-monthly Mim8 prophylaxis regimen.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NNC0365-3769 (Mim8)</intervention_name>
    <description>Mim8 will be injected into a skinfold on the stomach with a thin needle either once a week or once a month.</description>
    <arm_group_label>PPX - Mim8 PPXQW</arm_group_label>
    <arm_group_label>PPX- Mim8 PPXQM</arm_group_label>
    <arm_group_label>no PPX - Mim8 PPXQW - Mim8 PPXQW</arm_group_label>
    <arm_group_label>no PPX- no PPX - Mim8 PPXQW</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Informed consent obtained before any trial-related activities. Trial-related&#xD;
             activities are any procedures that are carried out as part of the trial, including&#xD;
             activities to determine suitability for the trial&#xD;
&#xD;
          -  Male or female with diagnosis of congenital haemophilia A of any severity based on&#xD;
             medical records&#xD;
&#xD;
          -  Patient has been prescribed, or in need of, treatment with factor VIII or bypassing&#xD;
             agent in the last 26 weeks prior to screening&#xD;
&#xD;
          -  Age above or equal to 12 years at the time of signing informed consent, Japan (The&#xD;
             legal age in Japan is 20 years or above) and Taiwan (The legal age in Taiwan is 20&#xD;
             years or above)&#xD;
&#xD;
          -  Body weight greater than or equal to 30 kg&#xD;
&#xD;
          -  Applicable to patients on emicizumab prophylaxis: patient is willing to discontinue&#xD;
             emicizumab at the time of screening&#xD;
&#xD;
          -  Applicable to patients treated with no prophylaxis prior to enrolment: greater than or&#xD;
             equal to 5 bleeds in the last 26 weeks prior to screening visit&#xD;
&#xD;
          -  Applicable to patients with FVIII activity greater than 1 percentage who are on&#xD;
             prophylactic treatment: greater than or equal to 1 bleed in the last 26 weeks prior to&#xD;
             screening visit&#xD;
&#xD;
          -  Willingness and ability to comply with scheduled visits and study procedures,&#xD;
             including the completion of diary and patient-reported outcomes questionnaires&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous participation in this trial. Participation is defined as signed informed&#xD;
             consent&#xD;
&#xD;
          -  Participation in any clinical trial of an approved or non-approved investigational&#xD;
             medicinal product, within 30 days (or 5 half-lives of the investigational medicinal&#xD;
             product, whichever is greater) before screening&#xD;
&#xD;
          -  Female who is pregnant, breast-feeding or intends to become pregnant or is of&#xD;
             child-bearing potential and not using a highly effective contraceptive method (highly&#xD;
             effective contraceptive measures as defined in the protocol or as required by local&#xD;
             regulation or practice). Breast feeding is allowed only during the run-in period&#xD;
&#xD;
          -  Any disorder, except for conditions associated with haemophilia A, which in the&#xD;
             investigator's opinion might jeopardise subject's safety or compliance with the&#xD;
             protocol&#xD;
&#xD;
          -  Known or suspected hypersensitivity to trial product(s), any constituents of the&#xD;
             product or to related products&#xD;
&#xD;
          -  Receipt of gene therapy at any given time point&#xD;
&#xD;
          -  Ongoing or planned ITI (immune tolerance induction) therapy&#xD;
&#xD;
          -  Major surgery planned at the time of screening&#xD;
&#xD;
          -  Known congenital or acquired coagulation disorders other than haemophilia A&#xD;
&#xD;
          -  Hepatic dysfunction defined as AST (aspartate aminotransferase) and/or ALT (alanine&#xD;
             aminotransferase) greater than 3 times the upper limit combined with total bilirubin&#xD;
             greater than 1.5 times the upper limit measured at screening&#xD;
&#xD;
          -  Renal impairment defined as estimated Glomerular Filtration Rate (eGFR) below or equal&#xD;
             to 30 ml/min/1.73 m^2 for serum creatinine measured at screening&#xD;
&#xD;
          -  Previous or current thromboembolic disease or events(Includes arterial and venous&#xD;
             thrombosis including myocardial infarction, thrombotic microangiography (TMA),&#xD;
             pulmonary embolism, cerebral infarction/thrombosis, deep vein thrombosis, other&#xD;
             clinically significant thromboembolic events and peripheral artery occlusion.) (with&#xD;
             the exception of previous catheter-associated thrombosis for which anti-thrombotic&#xD;
             treatment is not currently ongoing) or risk of thromboembolic disease, as evaluated by&#xD;
             investigator&#xD;
&#xD;
          -  Mental incapacity, unwillingness to cooperate, or a language barrier precluding&#xD;
             adequate understanding and cooperation&#xD;
&#xD;
          -  Other conditions (e.g. autoimmune disease) or laboratory abnormality that may increase&#xD;
             risk of bleeding or thrombosis as evaluated by the investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Transparency (dept. 1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novo Nordisk</last_name>
    <phone>(+1) 866-867-7178</phone>
    <email>clinicaltrials@novonordisk.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Innsbruck</city>
        <zip>A 6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Bruxelles</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Tianjing</city>
        <state>Tianjin</state>
        <zip>300020</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Praha 2</city>
        <zip>12000</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>København Ø</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Bron Cedex</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Kremlin-Bicêtre</city>
        <zip>94270</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Nantes Cedex 1</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Dublin</city>
        <zip>D08 A978</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Dublin</city>
        <zip>D12 N512</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Tel-Hashomer</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Firenze</city>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Milano</city>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Aichi</city>
        <zip>466-8560</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Saitama</city>
        <zip>330-8777</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Tokyo</city>
        <zip>160-0023</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Daejeon</city>
        <zip>302-799</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>05278</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Riga</city>
        <zip>LV-1002</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Kaunas</city>
        <zip>LT-50161</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Vilnius</city>
        <zip>08406</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Vilnius</city>
        <zip>LT-08661</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Utrecht</city>
        <zip>3584 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Lublin</city>
        <zip>20-093</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-556</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Riyadh</city>
        <zip>12713</zip>
        <country>Saudi Arabia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Novi Sad</city>
        <zip>21000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Martin</city>
        <zip>036 59</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Vranov nad Toplou</city>
        <zip>09327</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Johannesburg</city>
        <state>Gauteng</state>
        <zip>2013</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Parktown, Johannesburg</city>
        <state>Gauteng</state>
        <zip>2193</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Málaga</city>
        <zip>29009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>St. Gallen</city>
        <zip>9001</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Zürich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Taichung City</city>
        <zip>407</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Adana</city>
        <zip>01130</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Ankara</city>
        <zip>06500</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Antalya</city>
        <zip>01010</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Bornova-IZMIR</city>
        <zip>35100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Capa-ISTANBUL</city>
        <zip>35100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>China</country>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Ireland</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Latvia</country>
    <country>Lithuania</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Saudi Arabia</country>
    <country>Serbia</country>
    <country>Slovakia</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>Taiwan</country>
    <country>Turkey</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>September 13, 2021</study_first_submitted>
  <study_first_submitted_qc>September 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 22, 2021</study_first_posted>
  <last_update_submitted>November 12, 2021</last_update_submitted>
  <last_update_submitted_qc>November 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>According to the Novo Nordisk disclosure commitment on novonordisk-trials.com</ipd_description>
    <ipd_url>http://novonordisk-trials.com</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

